Barry Canton - 28 Jul 2026 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Reporting relationship: 10%+ Owner
Issuer ticker: DNA
Reported as of: 28 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jul 2026, 16:28:38 UTC
Prior SEC filing: 13 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Karen Tepichin, Attorney-in-Fact

Key filing fact

Barry Canton filed Form 4 for Ginkgo Bioworks Holdings, Inc. (DNA) on 30 Jul 2026.

Key facts

This page summarizes Barry Canton's Form 4 filing for Ginkgo Bioworks Holdings, Inc. (DNA).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 30 Jul 2026, 16:28.

Change

Previous filing in this sequence was filed on 13 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001882756 Primary reporting owner

Canton Barry

Relationship: 10%+ Owner
Address: C/O GINKGO BIOWORKS HOLDINGS, 27 DRYDOCK AVENUE, BOSTON
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Signature date: 30 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNA transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +35,736
Change %
Price
Shares after: 35,736
Date: 28 Jul 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 35,736
Exercise price
Footnotes: F1, F2

DNA transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +117,135
Change %
Price
Shares after: 117,135
Date: 28 Jul 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 117,135
Exercise price
Footnotes: F1, F3

DNA transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +39,038
Change %
Price
Shares after: 39,038
Date: 28 Jul 2026
Ownership: By Spouse
Underlying class: Class A Common Stock
Underlying amount: 39,038
Exercise price
Footnotes: F1, F2

DNA transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +127,423
Change %
Price
Shares after: 127,423
Date: 28 Jul 2026
Ownership: By Spouse
Underlying class: Class A Common Stock
Underlying amount: 127,423
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Footnote F2

The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.

Footnote F3

The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.